Azkarra Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
2ndary - Private
- Investors
-
1
Azkarra General Information
Description
Operator of a therapeutics company intended to target DNA damage repair and immune response pathways. The company aims to exploit molecular targets at the intersection of DNA Damage Repair (DDR) and immune response, advancing next-generation cancer therapeutics that offer novel therapies that enhance anti-tumor immunity by discovering small molecule modulators of DDR pathways, enabling patients access to new opportunities to cancer treatment and other diseases.
Contact Information
Website
www.azkarrabio.comCorporate Office
- 280 Utah Avenue
- Suite 250, South
- South San Francisco, CA 94080
- United States
Corporate Office
- 280 Utah Avenue
- Suite 250, South
- South San Francisco, CA 94080
- United States
Azkarra Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | Completed | Pre-Clinical Trials | ||||
| 3. Early Stage VC (Series B) | 12-Aug-2022 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | $2.5M | $3.2M | Completed | Pre-Clinical Trials | ||
| 1. Seed Round | $700K | $700K | Completed | Pre-Clinical Trials |
Azkarra Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A | ||||||||
| Seed-1 | 10,000,000 | $0.000100 | $0.06 | $0.06 | 1x | $0.06 | 15.24% | |
| Seed | 1,666,667 | $0.000100 | $0.06 | $0.06 | 1x | $0.06 | 2.54% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Azkarra Patents
Azkarra Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260317356-A1 | Small molecule modulators of ogg1 | Pending | 20-Apr-2023 | ||
| WO-2024220626-A1 | Small molecule modulators of ogg1 | Inactive | 20-Apr-2023 | ||
| EP-4594314-A1 | Pyridazin-3(2h)-one and pyridin-2(1h)-one parp inhibitor compounds | Pending | 30-Sep-2022 | ||
| US-20260109686-A1 | Pyridazin-3(2h)-one and pyridin-2(1h)-one parp inhibitor compounds | Pending | 30-Sep-2022 | ||
| WO-2024073133-A1 | Pyridazin-3(2h)-one and pyridin-2(1h)-one parp inhibitor compounds | Inactive | 30-Sep-2022 | C07D403/12 |
Azkarra Signals
Azkarra Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Pandect Bioventures | Venture Capital | Minority |
Azkarra FAQs
-
When was Azkarra founded?
Azkarra was founded in 2020.
-
Where is Azkarra headquartered?
Azkarra is headquartered in South San Francisco, CA.
-
What is the size of Azkarra?
Azkarra has 3 total employees.
-
What industry is Azkarra in?
Azkarra’s primary industry is Drug Discovery.
-
Is Azkarra a private or public company?
Azkarra is a Private company.
-
What is Azkarra’s current revenue?
The current revenue for Azkarra is .
-
How much funding has Azkarra raised over time?
Azkarra has raised $9.2M.
-
Who are Azkarra’s investors?
Pandect Bioventures has invested in Azkarra.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process